open access
Effective cardioprotection with early initiation of sacubitril-valsartan in a patient with breast cancer and cancer treatment-induced heart failure
Affiliations- Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland
- Department of Noninvasive Cardiac Diagnostics, Medical University of Gdansk, Gdańsk, Poland
open access
Abstract
Abstract
Supp./Additional Files (7)
About this articleTitle
Effective cardioprotection with early initiation of sacubitril-valsartan in a patient with breast cancer and cancer treatment-induced heart failure
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Clinical vignette
Published online
2022-06-15
Page views
163
Article views/downloads
116
DOI
10.33963/KP.a2022.0145
Pubmed
Authors
Grzegorz Sławiński
Hanna Jankowska
Aleksandra Liżewska-Springer
Ewa Lewicka
References (5)- Cho H, Lee S, Sim SH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Res Treat. 2020; 182(2): 333–343.
- Słowik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020; 78(2): 131–137.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Xi Q, Chen Z, Li T, et al. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction. J Int Med Res. 2022; 50(1): 3000605211067909.
- Martín-Garcia A, López-Fernández T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020; 7(2): 763–767.
